[go: up one dir, main page]

BRPI0511603A - método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados - Google Patents

método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados

Info

Publication number
BRPI0511603A
BRPI0511603A BRPI0511603-1A BRPI0511603A BRPI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A
Authority
BR
Brazil
Prior art keywords
treatment
disorders
nasps
sulfated polysaccharides
bleeding disorders
Prior art date
Application number
BRPI0511603-1A
Other languages
English (en)
Inventor
Kirk Johnson
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of BRPI0511603A publication Critical patent/BRPI0511603A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODO PARA O TRATAMENTO DE DISTúRBIOS DO SANGRAMENTO COM A UTILIZAçãO DE POLISSACARìDEOS SULFATADOS. São revelados para o tratamento de distúrbios do sangramento com a utilização de polissacarídeos sulfatados não anticoagulantes (NASPs) como pró-coagulantes. NASPs podem ser administrados como agentes únicos, ou em combinação com outros, ou com outras medicações (tais como fatores VII, VIII e IX) para promover hemostasia. Em particular, é descrito o uso de NASPS no tratamento de distúrbios do sangramento, incluindo distúrbios da coagulação congênitos, distúrbios da coagulação adquiridos e condições hemorrágicas induzidas por trauma.
BRPI0511603-1A 2004-05-27 2005-05-27 método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados BRPI0511603A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27
PCT/US2005/018669 WO2005117912A1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides

Publications (1)

Publication Number Publication Date
BRPI0511603A true BRPI0511603A (pt) 2008-01-02

Family

ID=35462725

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511603-1A BRPI0511603A (pt) 2004-05-27 2005-05-27 método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados

Country Status (15)

Country Link
US (4) US7767654B2 (pt)
EP (2) EP1748781B1 (pt)
JP (2) JP5232470B2 (pt)
CN (2) CN1984664B (pt)
AU (1) AU2005249465B2 (pt)
BR (1) BRPI0511603A (pt)
CA (1) CA2567495C (pt)
CY (1) CY1113705T1 (pt)
DK (1) DK1748781T3 (pt)
ES (2) ES2399277T3 (pt)
PL (1) PL1748781T3 (pt)
PT (1) PT1748781E (pt)
RU (1) RU2347574C2 (pt)
SI (1) SI1748781T1 (pt)
WO (1) WO2005117912A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1748781B1 (en) * 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
EP2010195A2 (en) * 2006-04-27 2009-01-07 Avigen, Inc. Fucoidans for reducing blood coagulation
CN101663326B (zh) 2007-02-23 2013-03-20 巴克斯特国际公司 从海藻提取物中纯化岩藻依聚糖的工艺方法
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
JP5896742B2 (ja) * 2008-08-22 2016-03-30 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 出血性障害を処置するための方法
JP5746041B2 (ja) * 2008-12-11 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ フィブリノーゲンと硫酸化多糖類に基づく製剤
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
US8632991B2 (en) * 2010-01-14 2014-01-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
ES2639641T3 (es) * 2010-04-20 2017-10-27 Octapharma Ag Nuevo agente estabilizante para proteínas farmacéuticas
SG10201508159SA (en) 2010-10-06 2015-10-29 Medimmune Ltd Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
CA2838793C (en) * 2011-07-19 2019-08-06 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
CA2861077A1 (en) * 2012-01-30 2013-08-08 Baxter International Inc. Non-anticoagulant sulfated or sulfonated polysaccharides
EP2809330B1 (en) 2012-01-30 2019-06-12 Baxalta GmbH Non-anticoagulant sulfated or sulfonated synthetic polymers
SI2827883T1 (sl) 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
US9417251B2 (en) 2012-08-14 2016-08-16 Baxalta GmbH Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
SG11202001824RA (en) 2016-08-31 2020-04-29 Oji Holdings Corp Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
CA3065747C (en) 2017-05-31 2024-10-01 Oji Holdings Corp Moisturizing composition comprising pentosan polysulfate
JP7167039B2 (ja) 2017-09-12 2022-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンの製造方法
KR102533822B1 (ko) 2017-12-20 2023-05-17 오지 홀딩스 가부시키가이샤 폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
CA2070813C (en) * 1990-11-05 1996-10-29 Hendrik Coenraad Hemker A method to determine the concentration of anticoagulants
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
JP3605414B2 (ja) * 1995-04-28 2004-12-22 タカラバイオ株式会社 糖化合物
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
EP0977995B1 (de) * 1997-04-25 2005-03-02 Pentapharm AG Verfahren zum funktionellen nachweis von störungen im protein c-system
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
CN1192780C (zh) * 1999-04-15 2005-03-16 宝生物工程株式会社 治疗剂
EP1279405A1 (en) * 2000-03-30 2003-01-29 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
ATE386538T1 (de) * 2001-02-05 2008-03-15 Novo Nordisk Healthcare Ag Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
ATE286075T1 (de) * 2001-10-24 2005-01-15 Takara Bio Inc Sulfatiertes fucan oligosaccharid
JP3941036B2 (ja) * 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1748781B1 (en) * 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
EP2010195A2 (en) * 2006-04-27 2009-01-07 Avigen, Inc. Fucoidans for reducing blood coagulation

Also Published As

Publication number Publication date
HK1103624A1 (en) 2007-12-28
DK1748781T3 (da) 2013-02-11
ES2482105T3 (es) 2014-08-01
PL1748781T3 (pl) 2013-05-31
US20090269325A1 (en) 2009-10-29
SI1748781T1 (sl) 2013-03-29
CN1984664B (zh) 2013-07-24
ES2399277T3 (es) 2013-03-27
EP1748781A4 (en) 2008-07-02
US8859526B2 (en) 2014-10-14
CN103251647A (zh) 2013-08-21
CY1113705T1 (el) 2016-06-22
US7767654B2 (en) 2010-08-03
JP5232470B2 (ja) 2013-07-10
US20110237512A1 (en) 2011-09-29
US8771973B2 (en) 2014-07-08
AU2005249465B2 (en) 2007-12-06
EP2165711B1 (en) 2014-05-21
EP1748781A1 (en) 2007-02-07
CN1984664A (zh) 2007-06-20
JP2012046551A (ja) 2012-03-08
CA2567495C (en) 2014-02-18
CA2567495A1 (en) 2005-12-15
RU2006146801A (ru) 2008-07-10
HK1142276A1 (en) 2010-12-03
JP2008500367A (ja) 2008-01-10
EP1748781B1 (en) 2012-12-19
AU2005249465A1 (en) 2005-12-15
WO2005117912A1 (en) 2005-12-15
US20050282771A1 (en) 2005-12-22
EP2165711A1 (en) 2010-03-24
US20120129777A1 (en) 2012-05-24
PT1748781E (pt) 2013-01-22
RU2347574C2 (ru) 2009-02-27
US7829549B2 (en) 2010-11-09

Similar Documents

Publication Publication Date Title
BRPI0511603A (pt) método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados
Strecker-McGraw et al. Soft tissue wounds and principles of healing
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
MX2009001323A (es) Aposito solido para tratar tejido herido.
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
PH12013501791B1 (en) Uses of dpp-iv inhibitors
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
WO2007038686A3 (en) Amniotic membrane preparations and purified compositions and methods of use
ATE269113T1 (de) Sprühfähige wundversorgungszusammensetzung
WO2007100675A3 (en) Collagenase for treating cellulite
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BR112016009954A2 (pt) terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
WO2007100590A3 (en) Methods for treating cellulite
SE0200005D0 (sv) New use
BRPI0516134A (pt) neurotoxinas de clostridium para uso na cicatrização de tecidos
ATE405276T1 (de) Pharmazeutische gel-zusammensetzung
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.